Injury to the liver remains a significant therapeutic challenge, with limited treatment options and a high burden on global health. Ace Therapeutics is a specialized partner in preclinical drug development, dedicated exclusively to advancing innovative therapies for liver injury and related disorders. Ace Therapeutics delivers comprehensive preclinical solutions spanning target validation, lead optimization, and IND-enabling studies, ensuring a seamless transition from early discovery to clinical readiness. Our scientific team brings deep expertise in liver biology and injury mechanisms, supported by advanced in vitro and in vivo platforms tailored to model complex hepatic pathologies. Rigorous adherence to regulatory standards underpins every stage of our process, providing robust and reproducible data that meet the expectations of global health authorities. With a focus on scientific rigor and technological innovation, Ace Therapeutics is committed to accelerating the development of transformative therapeutics for liver injury. We partner with biopharmaceutical innovators to drive efficient, high-quality drug candidates toward clinical success.
